应答者分层标志物的跨体质稳定性:基线菌群指纹能否在偏颇质与平和质间通用

Written by

in

Language

Evidence level: B

同一个菌属标志物,在痰湿体质里指向”偏颇”,在 IBS 场景里指向”应答”——应答标志物能否跨体质稳定复现,是辨体论治个体化的第一道真命题。

正文

中医体质学说认为,九种体质各有偏颇,干预应当”辨体论治”。但当干预对象换成肠道菌群时,一个关键问题浮出水面:用来预判”谁会受益”的生物标志物,是否在偏颇质与平和质之间通用?如果标志物方向随体质翻转,那么从一种体质人群中训练出来的应答模型,搬到另一种体质就会失灵。这不是纯思辨问题——证据已经走到能检验它的门口,只是还没有人把检验做出来。

先看第一块证据:基线菌群确实能预测益生菌应答。IBS-D 患者的枯草芽孢杆菌+粪肠球菌试验中,基线菌群即可区分应答者与无应答者,腹痛缓解应答者富集 Atopobium 与 R. gnavus,无应答者则富集 Prevotella 与 Faecalibacterium(PMID 36281578);另一项 IBS-D 多菌株 RCT 同样发现 E. faecalis 与 L. lactis 是无应答的生物标志物,而 Fusicatenibacter saccharivorans 的上升与症状改善相关(PMID 36250371)。老年人群研究更进一步:应答者基线 α 多样性显著更高(Shannon p=0.00058),无应答者富集梭菌与志贺菌(PMID 26441879)。三条独立证据指向同一结论——”谁吃有效”在干预前就写在菌群里,应答预测在原理上成立。

第二块证据:体质本身有可量化的菌群指纹。肥胖伴痰湿体质者,产生短链脂肪酸、抗炎并增强肠屏障的 Faecalibacterium 显著耗竭,Prevotella 富集,且菌群分类器能以 AUC=0.83 区分痰湿与非痰湿肥胖者(PMID 35719350);高血压前期的痰湿质人群同样呈现可区分的菌群构成,随机森林给出 Alistipes、Parabacteroides 等判别菌属(PMID 40104285)。阳虚质 RCT 显示,干预后菌群向平和质方向恢复,而平和质本身具有更高的菌群多样性(PMID 34107861)。九体质对比研究进一步发现,平和质供体的 FMT 合格率显著更高,且不同体质供体的抗肥胖效果不同(PMID 41853345)。虚性体质人群还呈现 E. coli、C. bolteae、R. gnavus 等标志菌富集,与贫血倾向相关(PMID 39360281)。体质差异确实编码在菌群里。

但跨体质稳定性的考验恰恰藏在这里。注意一个微妙的反向信号:在 IBS-D 场景中,Faecalibacterium 富集指向”无应答”(PMID 36281578);而在痰湿体质场景中,Faecalibacterium 耗竭指向”偏颇”(PMID 35719350)。同一菌属在不同人群、不同适应症中方向相反。这有两种解读:其一,标志物是场景特异的,应答方向取决于疾病背景与干预机制;其二,菌属层面的信号过于粗糙,需要种株层面或功能层面(如产丁酸通路)才能稳定。无论哪种,都意味着”跨体质复制标志物”不能想当然——必须设计直接检验。

373 要回答的核心问题:基线体质评分严重度与关键菌属丰度(Faecalibacterium 等)预测体质评分改善幅度时,标志物在偏颇质(痰湿/阳虚/湿热)与平和质间的方向与量级是否一致。执行骨架:三种偏颇质+平和质分层入组,统一菌群干预 RCT,基线同步采集 CCMQ 评分与 16S/宏基因组,以最小临床重要差异(MCID)定义应答,逐体质亚组检验标志物方向与量级一致性,再以机器学习建模并做跨体质外部验证。若标志物方向一致,辨体模型的泛化性得到支撑,问卷严重度与菌群指纹可以合并成一套跨体质预测器;若方向翻转,则”一菌标志”不可跨体质套用,必须按体质定制模型或升级到功能通路面。类似的方向性翻转在冥想生理学中已有先例——急性期血氧下降、长期练习后基线上升(PMID 28840941),说明同一指标在不同时间尺度上可以反转,跨体质反转并非不可想象。

这一步直接呼应易学”因地制宜、因人制宜”的辨证思维——同一个象,在不同的局里含义可以截然不同;标志物若不能跨体质稳定,那么辨体论治就永远停留在”分类”层面,进不到”预测”层面。

证据与局限

已验证: 基线菌群可预测益生菌应答(IBS-D 双研究与老年队列,PMID 36281578/36250371/26441879);痰湿等偏颇体质存在可量化的菌群指纹(PMID 35719350/40104285);平和质菌群多样性更高、FMT 供体合格率更高(PMID 34107861/41853345);虚性体质有标志菌富集(PMID 39360281)。

部分验证: Faecalibacterium 作为肠道健康生物标志物被广泛支持(PMID 28045459/37451743),但同一菌属在 IBS 应答场景与体质场景中方向相反,种株/功能层面的稳定性尚未澄清。

待验证: 标志物跨体质的方向与量级一致性;体质评分严重度在菌群指纹之上的增量预测力;功能通路(产丁酸)是否比菌属丰度更跨体质稳定。

相关阅读

证据等级: B
参考文献: PMID 36281578, PMID 36250371, PMID 26441879, PMID 35719350, PMID 40104285, PMID 34107861, PMID 41853345, PMID 39360281, PMID 28045459, PMID 37451743, PMID 28840941


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Cross-ethnic stability of responder stratification biomarkers: Can baseline microbiome fingerprints be universally applied between Biased and Harmonious constitutions?

Evidence level: B

A marker belonging to the same genus may signal “deficiency” in a Phlegm-Damp constitution yet signal “response” in an IBS context—whether responder markers can be stably replicated across constitutions is the first genuine proposition in the theory of differentiation-based treatment.

Main Text

Traditional Chinese medicine constitution theory posits that each of the nine constitutions possesses a specific deviation, and intervention should follow “differentiation-based treatment.” However, when the intervention target shifts to gut microbiota, a critical question emerges: Are biological markers used to predict “who will benefit” universal between deficient and harmonious constitutions? If marker direction flips with constitution, a response model trained on one constitutional group will fail when applied to another. This is not merely speculative; evidence has reached the threshold where it can be tested, yet no one has yet conducted such a test.

First piece of evidence: Baseline microbiota can predict probiotic response. In trials involving Bacillus subtilis and Enterococcus faecalis in IBS-D patients, baseline microbiota distinguished responders from non-responders. Responders with abdominal pain relief enriched in Atopobium and R. gnavus, while non-responders enriched in Prevotella and Faecalibacterium (PMID 36281578); another IBS-D multi-strain RCT similarly identified E. faecalis and L. lactis as markers of non-response, whereas the rise of Fusicatenibacter saccharivorans correlated with symptom improvement (PMID 36250371). Older adult studies further indicate that responders exhibited significantly higher baseline alpha diversity (Shannon p=0.00058), while non-responders enriched in Clostridia and Shigella (PMID 26441879). Three independent lines of evidence point to a single conclusion: “who benefits” is written in the microbiome prior to intervention, and response prediction holds theoretically.

Second piece of evidence: Constitutions themselves possess quantifiable microbiome fingerprints. In obese individuals with Phlegm-Damp constitution, Faecalibacterium, which produces short-chain fatty acids, exerts anti-inflammatory effects, and strengthens the intestinal barrier, is significantly depleted, while Prevotella enriches; furthermore, microbiome classifiers can distinguish Phlegm-Damp from non-Phlegm-Damp obesity with an AUC of 0.83 (PMID 35719350). Pre-hypertensive individuals with Phlegm-Damp constitution similarly exhibit distinguishable microbiome compositions, where random forests identify discriminant genera such as Alistipes and Parabacteroides (PMID 40104285). A RCT on Yang Deficiency constitution showed that post-intervention microbiota recovered toward the Harmonious direction, while the Harmonious constitution itself possesses higher microbiome diversity (PMID 34107861). A nine-constitution comparative study further revealed that FMT success rates were significantly higher in Harmonious constitution donors, and anti-obesity effects varied across different constitution donors (PMID 41853345). Individuals with Deficiency constitutions also exhibited enrichment of marker bacteria such as E. coli, C. bolteae, and R. gnavus, correlating with anemia tendencies (PMID 39360281). Constitutional differences are indeed encoded in the microbiome.

Yet the test of cross-constitution stability hides precisely here. Note a subtle reverse signal: in the IBS-D context, Faecalibacterium enrichment signals “non-response” (PMID 36281578); whereas in the Phlegm-Damp context, Faecalibacterium depletion signals “deficiency” (PMID 35719350). The same genus exhibits opposite directions across different populations and indications. Two interpretations arise: first, markers are context-specific, with response direction dependent on disease background and intervention mechanisms; second, signals at the genus level are too coarse, requiring strain-level or functional-level resolution (e.g., butyrate production pathways) for stability. Regardless, this implies that “cross-constitution replication of markers” cannot be assumed—direct testing must be designed.

373 Core Question to Answer: When predicting the magnitude of constitution score improvement based on baseline constitution severity scores and key genus abundance (e.g., Faecalibacterium), whether the direction and magnitude of markers remain consistent between deficient constitutions (Phlegm-Damp/Yang Deficiency/Damp-Heat) and the Harmonious constitution. Execution Framework: Stratify enrollment into three deficient types plus one Harmonious type, conduct a unified microbiome intervention RCT, collect CCMQ scores and 16S/metagenomic data synchronously at baseline, define response using the Minimum Clinically Important Difference (MCID), test marker direction and magnitude consistency within each constitutional subgroup sequentially, then build machine learning models for cross-constitution external validation. If marker direction remains consistent, the generalizability of the differentiation model is supported, allowing questionnaire severity scores and microbiome fingerprints to be merged into a single cross-constitution predictor; if direction flips, then “one-genus marker” cannot be applied across constitutions, necessitating constitution-specific model customization or upgrading to functional pathway levels. Similar directional reversals have precedents in meditation physiology—blood oxygen decreases during the acute phase but rises at baseline after long-term practice (PMID 28840941)—indicating that reversal across different temporal scales is not unimaginable, let alone across constitutions.

This step directly resonates with the Yijing Studies concept of “adapting treatment to local conditions and individuals” (因地制宜、因人制宜) in differentiation-based thinking—the same image can hold entirely different meanings within different configurations; if markers cannot be stably replicated across constitutions, differentiation-based treatment will forever remain at the “classification” level and never advance to the “prediction” level.

Evidence and Limitations

Verified: Baseline microbiota predicts probiotic response (IBS-D dual studies and older cohort, PMID 36281578/36250371/26441879); quantifiable microbiome fingerprints exist for deficient constitutions like Phlegm-Damp (PMID 35719350/40104285); Harmonious constitution exhibits higher microbiome diversity and higher FMT donor success rates (PMID 34107861/41853345); Deficiency constitutions show marker genus enrichment (PMID 39360281).

Partially Verified: Faecalibacterium is widely supported as an intestinal health biomarker (PMID 28045459/37451743), yet the same genus shows opposite directions in IBS response contexts versus constitution contexts, and stability at strain/functional levels remains unclarified.

Pending Verification: Directional and magnitude consistency of markers across constitutions; incremental predictive power of constitution severity scores above microbiome fingerprints; whether functional pathways (butyrate production) are more cross-constitution stable than genus abundance.

Related Reading

Evidence Level: B
References: PMID 36281578, PMID 36250371, PMID 26441879, PMID 35719350, PMID 40104285, PMID 34107861, PMID 41853345, PMID 39360281, PMID 28045459, PMID 37451743, PMID 28840941


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *